Drug Profile
Research programme: ghrelin antagonists - Elixir
Alternative Names: EX-1350Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Elixir Pharmaceuticals
- Class Small molecules
- Mechanism of Action Ghrelin antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity; Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (PO)
- 10 Jun 2008 Pharmacodynamics data from a preclinical study in Type-2 diabetes presented at the 68th Scientific Sessions of the American Diabetes Association (ADA-2008)